{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:31:12Z","timestamp":1793845872244,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cabrini Medical Staff Scholarship"},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","award":["Postdoctoral Scholarship"],"award-info":[{"award-number":["Postdoctoral Scholarship"]}],"id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","award":["Driving Research Momentum Fellowship"],"award-info":[{"award-number":["Driving Research Momentum Fellowship"]}],"id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","award":["Operational Infrastructure Support Program"],"award-info":[{"award-number":["Operational Infrastructure Support Program"]}],"id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","award":["Operational Infrastructure Support Program"],"award-info":[{"award-number":["Operational Infrastructure Support Program"]}],"id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","award":["Operational Infrastructure Support Program"],"award-info":[{"award-number":["Operational Infrastructure Support Program"]}],"id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","award":["Operational Infrastructure Support Program"],"award-info":[{"award-number":["Operational Infrastructure Support Program"]}],"id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1195713"],"award-info":[{"award-number":["1195713"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90516-z","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:28:11Z","timestamp":1741771691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective audit reviewing accuracy of clinical diagnosis of geographic atrophy in a single centre private tertiary retinal practice in Australia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-3769","authenticated-orcid":false,"given":"Demi","family":"Markakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-2870","authenticated-orcid":false,"given":"Alexis Ceecee","family":"Britten-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn H.","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-7416","authenticated-orcid":false,"given":"Thomas L.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-3759","authenticated-orcid":false,"given":"Anthony J.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7381-285X","authenticated-orcid":false,"given":"Nathan M.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0526-9371","authenticated-orcid":false,"given":"Weng","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-8002","authenticated-orcid":false,"given":"Simon","family":"Skalicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-084X","authenticated-orcid":false,"given":"Lauren N.","family":"Ayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9756-1098","authenticated-orcid":false,"given":"Heather G.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"90516_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris 3rd","year":"2013","unstructured":"Ferris, F. L. 3rd et al. Clinical classification of age-related macular degeneration. Ophthalmology 120, 844\u2013851. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.036 (2013).","journal-title":"Ophthalmology"},{"key":"90516_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.preteyeres.2016.04.008","volume":"53","author":"KN Khan","year":"2016","unstructured":"Khan, K. N. et al. Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res. 53, 70\u2013106. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.008 (2016).","journal-title":"Prog Retin Eye Res."},{"key":"90516_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cxo.12842","volume":"102","author":"AJ Wightman","year":"2019","unstructured":"Wightman, A. J. & Guymer, R. H. Reticular pseudodrusen: current understanding. Clin. Exp. Optom. 102, 455\u2013462. https:\/\/doi.org\/10.1111\/cxo.12842 (2019).","journal-title":"Clin. Exp. Optom."},{"key":"90516_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. 48, 134\u2013143. https:\/\/doi.org\/10.1038\/ng.3448 (2016).","journal-title":"Nat. Genet."},{"key":"90516_CR5","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub4","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G. & Hawkins, B. S. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst. Rev. 3, CD005139. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"90516_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/s0161-6420(91)32186-9","volume":"98","author":"R Klein","year":"1991","unstructured":"Klein, R. et al. The Wisconsin age-related maculopathy grading system. Ophthalmology 98, 1128\u20131134. https:\/\/doi.org\/10.1016\/s0161-6420(91)32186-9 (1991).","journal-title":"Ophthalmology"},{"key":"90516_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer, R. H. & Campbell, T. G. Age-related macular degeneration. Lancet 401, 1459\u20131472. https:\/\/doi.org\/10.1016\/S0140-6736(22)02609-5 (2023).","journal-title":"Lancet"},{"key":"90516_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao, D. S. et al. Complement C3 inhibitor Pegcetacoplan for Geographic Atrophy secondary to age-related Macular Degeneration: a randomized phase 2 trial. Ophthalmology 127, 186\u2013195. https:\/\/doi.org\/10.1016\/j.ophtha.2019.07.011 (2020).","journal-title":"Ophthalmology"},{"key":"90516_CR9","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani, A. M. et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402, 1449\u20131458. https:\/\/doi.org\/10.1016\/S0140-6736(23)01583-0 (2023).","journal-title":"Lancet"},{"key":"90516_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe, G. J. et al. C5 inhibitor Avacincaptad Pegol for Geographic Atrophy due to age-related Macular Degeneration: a Randomized Pivotal Phase 2\/3 Trial. Ophthalmology 128, 576\u2013586. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.027 (2021).","journal-title":"Ophthalmology"},{"key":"90516_CR11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","volume":"124","author":"EM Stone","year":"2017","unstructured":"Stone, E. M. et al. Clinically focused Molecular Investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology 124, 1314\u20131331. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.008 (2017).","journal-title":"Ophthalmology"},{"key":"90516_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2147\/OPTH.S293381","volume":"15","author":"RM Coco-Martin","year":"2021","unstructured":"Coco-Martin, R. M., Diego-Alonso, M., Orduz-Montana, W. A., Sanabria, M. R. & Sanchez-Tocino, H. Descriptive study of a cohort of 488 patients with inherited retinal dystrophies. Clin. Ophthalmol. 15, 1075\u20131084. https:\/\/doi.org\/10.2147\/OPTH.S293381 (2021).","journal-title":"Clin. Ophthalmol."},{"key":"90516_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.preteyeres.2013.11.001","volume":"39","author":"NT Saksens","year":"2014","unstructured":"Saksens, N. T. et al. Macular dystrophies mimicking age-related macular degeneration. Prog Retin Eye Res. 39, 23\u201357. https:\/\/doi.org\/10.1016\/j.preteyeres.2013.11.001 (2014).","journal-title":"Prog Retin Eye Res."},{"key":"90516_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.65.6.31","volume":"65","author":"TAC de Guimaraes","year":"2024","unstructured":"de Guimaraes, T. A. C. et al. A long-term Retrospective Natural History Study of EFEMP1-Associated autosomal Dominant Drusen. Invest. Ophthalmol. Vis. Sci. 65, 31. https:\/\/doi.org\/10.1167\/iovs.65.6.31 (2024).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"90516_CR15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.ophtha.2019.03.013","volume":"126","author":"RL Taylor","year":"2019","unstructured":"Taylor, R. L. et al. Loss-of-function mutations in the CFH Gene affecting alternatively encoded factor H-like 1 protein cause Dominant early-Onset Macular Drusen. Ophthalmology 126, 1410\u20131421. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.013 (2019).","journal-title":"Ophthalmology"},{"key":"90516_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.ophtha.2015.04.035","volume":"122","author":"M Gliem","year":"2015","unstructured":"Gliem, M. et al. Reticular pseudodrusen in Sorsby Fundus dystrophy. Ophthalmology 122, 1555\u20131562. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.035 (2015).","journal-title":"Ophthalmology"},{"key":"90516_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1097\/IAE.0000000000001113","volume":"36","author":"C Cukras","year":"2016","unstructured":"Cukras, C. et al. Longitudinal structural changes in late-onset retinal degeneration. Retina 36, 2348\u20132356. https:\/\/doi.org\/10.1097\/IAE.0000000000001113 (2016).","journal-title":"Retina"},{"key":"90516_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.04.001","author":"A Antropoli","year":"2024","unstructured":"Antropoli, A. et al. Extensive Macular Atrophy with Pseudodrusen-like appearance (EMAP): progression kinetics and late-stage findings. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2024.04.001 (2024).","journal-title":"Ophthalmology"},{"key":"90516_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/13816810.2015.1101777","volume":"37","author":"J Savige","year":"2016","unstructured":"Savige, J. et al. Retinal disease in the C3 glomerulopathies and the risk of impaired vision. Ophthalmic Genet. 37, 369\u2013376. https:\/\/doi.org\/10.3109\/13816810.2015.1101777 (2016).","journal-title":"Ophthalmic Genet."},{"key":"90516_CR20","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jcjo.2014.12.016","volume":"50","author":"RA Alshareef","year":"2015","unstructured":"Alshareef, R. A., Bansal, A. S., Chiang, A. & Kaiser, R. S. Macular atrophy in a case of abetalipoproteinemia as only ocular clinical feature. Can. J. Ophthalmol. 50, e43\u201346. https:\/\/doi.org\/10.1016\/j.jcjo.2014.12.016 (2015).","journal-title":"Can. J. Ophthalmol."},{"key":"90516_CR21","doi-asserted-by":"publisher","first-page":"100827","DOI":"10.1016\/j.preteyeres.2019.100827","volume":"77","author":"AV Garafalo","year":"2020","unstructured":"Garafalo, A. V. et al. Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives. Prog Retin Eye Res. 77, 100827. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.100827 (2020).","journal-title":"Prog Retin Eye Res."},{"key":"90516_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40259-020-00453-8","volume":"34","author":"PI Fuller-Carter","year":"2020","unstructured":"Fuller-Carter, P. I., Basiri, H., Harvey, A. R. & Carvalho, L. S. Focused update on AAV-Based gene therapy clinical trials for inherited retinal degeneration. BioDrugs 34, 763\u2013781. https:\/\/doi.org\/10.1007\/s40259-020-00453-8 (2020).","journal-title":"BioDrugs"},{"key":"90516_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40123-023-00862-2","volume":"13","author":"AS Brar","year":"2024","unstructured":"Brar, A. S. et al. Gene Therapy for Inherited Retinal Diseases: from Laboratory Bench to Patient Bedside and Beyond. Ophthalmol. Ther. 13, 21\u201350. https:\/\/doi.org\/10.1007\/s40123-023-00862-2 (2024).","journal-title":"Ophthalmol. Ther."},{"key":"90516_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/cge.13447","volume":"94","author":"E Kersten","year":"2018","unstructured":"Kersten, E. et al. Genetic screening for macular dystrophies in patients clinically diagnosed with dry age-related macular degeneration. Clin. Genet. 94, 569\u2013574. https:\/\/doi.org\/10.1111\/cge.13447 (2018).","journal-title":"Clin. Genet."},{"key":"90516_CR25","doi-asserted-by":"publisher","first-page":"2250538","DOI":"10.1080\/07853890.2023.2250538","volume":"55","author":"AC Britten-Jones","year":"2023","unstructured":"Britten-Jones, A. C. et al. Characterising the diagnosis of genetic maculopathies in a real-world private tertiary retinal practice in Australia: protocol for a retrospective clinical audit. Ann. Med. 55, 2250538. https:\/\/doi.org\/10.1080\/07853890.2023.2250538 (2023).","journal-title":"Ann. Med."},{"key":"90516_CR26","doi-asserted-by":"publisher","unstructured":"Sadda, S. R. et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology 125, 537\u2013548 (2018). https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028","DOI":"10.1016\/j.ophtha.2017.09.028"},{"key":"90516_CR27","doi-asserted-by":"publisher","first-page":"101017","DOI":"10.1016\/j.preteyeres.2021.101017","volume":"88","author":"Z Wu","year":"2022","unstructured":"Wu, Z., Fletcher, E. L., Kumar, H., Greferath, U. & Guymer, R. H. Reticular pseudodrusen: a critical phenotype in age-related macular degeneration. Prog Retin Eye Res. 88, 101017. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.101017 (2022).","journal-title":"Prog Retin Eye Res."},{"key":"90516_CR28","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1111\/aos.13602","volume":"96","author":"F Pichi","year":"2018","unstructured":"Pichi, F., Abboud, E. B., Ghazi, N. G. & Khan, A. O. Fundus autofluorescence imaging in hereditary retinal diseases. Acta Ophthalmol. 96, e549\u2013e561. https:\/\/doi.org\/10.1111\/aos.13602 (2018).","journal-title":"Acta Ophthalmol."},{"key":"90516_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 42, 377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010 (2009).","journal-title":"J. Biomed. Inf."},{"key":"90516_CR30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh, M. L. Interrater reliability: the kappa statistic. Biochem. Med. (Zagreb). 22, 276\u2013282 (2012).","journal-title":"Biochem. Med. (Zagreb)"},{"key":"90516_CR31","doi-asserted-by":"publisher","first-page":"20344","DOI":"10.1038\/s41598-020-77566-1","volume":"10","author":"E Borrelli","year":"2020","unstructured":"Borrelli, E. et al. Rate of misdiagnosis and clinical usefulness of the correct diagnosis in exudative neovascular maculopathy secondary to AMD versus pachychoroid disease. Sci. Rep. 10, 20344. https:\/\/doi.org\/10.1038\/s41598-020-77566-1 (2020).","journal-title":"Sci. Rep."},{"key":"90516_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12886-016-0395-x","volume":"17","author":"DT Dias","year":"2017","unstructured":"Dias, D. T., Ushida, M., Battistella, R., Dorairaj, S. & Prata, T. S. Neurophthalmological conditions mimicking glaucomatous optic neuropathy: analysis of the most common causes of misdiagnosis. BMC Ophthalmol. 17, 2. https:\/\/doi.org\/10.1186\/s12886-016-0395-x (2017).","journal-title":"BMC Ophthalmol."},{"key":"90516_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1515\/dx-2019-0104","volume":"8","author":"DE Newman-Toker","year":"2021","unstructured":"Newman-Toker, D. E. et al. Rate of diagnostic errors and serious misdiagnosis-related harms for major vascular events, infections, and cancers: toward a national incidence estimate using the Big Three. Diagnosis (Berl). 8, 67\u201384. https:\/\/doi.org\/10.1515\/dx-2019-0104 (2021).","journal-title":"Diagnosis (Berl)"},{"key":"90516_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/archinternmed.2010.146","volume":"170","author":"L Zwaan","year":"2010","unstructured":"Zwaan, L. et al. Patient record review of the incidence, consequences, and causes of diagnostic adverse events. Arch. Intern. Med. 170, 1015\u20131021. https:\/\/doi.org\/10.1001\/archinternmed.2010.146 (2010).","journal-title":"Arch. Intern. Med."},{"key":"90516_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/bmjqs-2013-002627","volume":"23","author":"H Singh","year":"2014","unstructured":"Singh, H., Meyer, A. N. & Thomas, E. J. The frequency of diagnostic errors in outpatient care: estimations from three large observational studies involving US adult populations. BMJ Qual. Saf. 23, 727\u2013731. https:\/\/doi.org\/10.1136\/bmjqs-2013-002627 (2014).","journal-title":"BMJ Qual. Saf."},{"key":"90516_CR36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/sj.eye.6702276","volume":"21","author":"J Khan","year":"2007","unstructured":"Khan, J. & Damato, B. E. Accuracy of choroidal melanoma diagnosis by general ophthalmologists: a prospective study. Eye (Lond). 21, 595\u2013597. https:\/\/doi.org\/10.1038\/sj.eye.6702276 (2007).","journal-title":"Eye (Lond)"},{"key":"90516_CR37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2147\/RMHP.S307527","volume":"14","author":"W Zhu","year":"2021","unstructured":"Zhu, W. et al. Agreement of Optic nerve head evaluation of primary Open-Angle Glaucoma between General ophthalmologists and Glaucoma specialists. Risk Manag Healthc. Policy. 14, 1815\u20131822. https:\/\/doi.org\/10.2147\/RMHP.S307527 (2021).","journal-title":"Risk Manag Healthc. Policy"},{"key":"90516_CR38","doi-asserted-by":"publisher","first-page":"e0000341","DOI":"10.1371\/journal.pdig.0000341","volume":"3","author":"AJ Thirunavukarasu","year":"2024","unstructured":"Thirunavukarasu, A. J. et al. Large language models approach expert-level clinical knowledge and reasoning in ophthalmology: a head-to-head cross-sectional study. PLOS Digit. Health. 3, e0000341. https:\/\/doi.org\/10.1371\/journal.pdig.0000341 (2024).","journal-title":"PLOS Digit. Health"},{"key":"90516_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajo.2022.12.027","volume":"249","author":"AC Britten-Jones","year":"2023","unstructured":"Britten-Jones, A. C. et al. The Diagnostic yield of Next Generation sequencing in inherited retinal diseases: a systematic review and Meta-analysis. Am. J. Ophthalmol. 249, 57\u201373. https:\/\/doi.org\/10.1016\/j.ajo.2022.12.027 (2023).","journal-title":"Am. J. Ophthalmol."},{"key":"90516_CR40","doi-asserted-by":"publisher","unstructured":"Hitti-Malin, R. J. et al. Towards uncovering the role of Incomplete Penetrance in Maculopathies through sequencing of 105 Disease-Associated genes. Biomolecules 14 https:\/\/doi.org\/10.3390\/biom14030367 (2024).","DOI":"10.3390\/biom14030367"},{"key":"90516_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman, A. E. G. et al. The complications of myopia: a review and Meta-analysis. Invest. Ophthalmol. Vis. Sci. 61, 49. https:\/\/doi.org\/10.1167\/iovs.61.4.49 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"90516_CR42","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00417-023-06088-z","volume":"261","author":"D Oncel","year":"2023","unstructured":"Oncel, D. et al. Drusen morphometrics on optical coherence tomography in eyes with age-related macular degeneration and normal aging. Graefes Arch. Clin. Exp. Ophthalmol. 261, 2525\u20132533. https:\/\/doi.org\/10.1007\/s00417-023-06088-z (2023).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"90516_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.gim.2021.10.013","volume":"24","author":"AC Britten-Jones","year":"2021","unstructured":"Britten-Jones, A. C. et al. The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: a systematic review. Genet. Med. 24, 521\u2013534. https:\/\/doi.org\/10.1016\/j.gim.2021.10.013 (2021).","journal-title":"Genet. Med."},{"key":"90516_CR44","unstructured":"Administration., U. S. F. a. D. FDA Approves Novel gene Therapy to Treat Patients with a rare form of Inherited Vision loss (U.S. Food and Drug Administration, 2017)."},{"key":"90516_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.preteyeres.2018.03.003","volume":"65","author":"ER Burnight","year":"2018","unstructured":"Burnight, E. R. et al. CRISPR-Cas9 genome engineering: treating inherited retinal degeneration. Prog Retin Eye Res. 65, 28\u201349. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.03.003 (2018).","journal-title":"Prog Retin Eye Res."},{"key":"90516_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13287-023-03526-x","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen, X., Xu, N., Li, J., Zhao, M. & Huang, L. Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis. Stem Cell. Res. Ther. 14, 286. https:\/\/doi.org\/10.1186\/s13287-023-03526-x (2023).","journal-title":"Stem Cell. Res. Ther."},{"key":"90516_CR47","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","volume":"28","author":"SR Russell","year":"2022","unstructured":"Russell, S. R. et al. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial. Nat. Med. 28, 1014\u20131021. https:\/\/doi.org\/10.1038\/s41591-022-01755-w (2022).","journal-title":"Nat. Med."},{"key":"90516_CR48","first-page":"3785","volume":"64","author":"EA Pierce","year":"2023","unstructured":"Pierce, E. A. et al. Safety and efficacy of EDIT-101 for treatment of CEP290-associated retinal degeneration. Investig. Ophthalmol. Vis. Sci. 64, 3785\u20133785 (2023).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"90516_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz, S. D. et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet 385, 509\u2013516. https:\/\/doi.org\/10.1016\/s0140-6736(14)61376-3 (2015).","journal-title":"Lancet"},{"key":"90516_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.oret.2024.04.003","volume":"8","author":"A Mahmoudi","year":"2024","unstructured":"Mahmoudi, A. et al. Predictive factors influencing the evolution of Acquired Vitelliform lesions in Intermediate Age-related Macular Degeneration eyes. Ophthalmol. Retina. 8, 367\u2013375. https:\/\/doi.org\/10.1016\/j.oret.2024.04.003 (2024).","journal-title":"Ophthalmol. Retina"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90516-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:53:47Z","timestamp":1741812827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90516-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90516"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90516-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.N.A. has been a consultant to Novartis and Apellis Pharmaceuticals and currently consults for Kiora Pharmaceuticals. T.L.E. has received a research grant from Novartis Pharmaceuticals. R.H.G. is a member of advisory boards of Bayer, Novartis, Apellis Pharmaceuticals, Roche-Genentech, Belite Bio, Ocular therapeutix, complement therapeutics, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Janssen, AbbVie and Astellas. A.J.H. is a member of an advisory board for AbbVie, receives research support from Novotech, Genentech and Roche and is a paid lecturer for UCB. N.M.K. has received research funding and\/or honoraria from Alcon, Allergan\/Abbvie, Bayer, Glaukos, Johnson & Johnson Vision, NOVA Eye Medical, Santen, and VividWhite. H.G.M. has been a member of advisory boards of Novartis, Apellis Pharmaceuticals, Roche-Genentech and Janssen Pharmaceuticals, and has received travel funding from Bayer and Roche-Genentech. S.S. is the director of Eyeonic Pty Ltd which owns patent WO2021051162A1 regarding online circular contrast perimetry. The remaining authors report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8528"}}